181 related articles for article (PubMed ID: 31452441)
21. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
22. Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter.
Schweppe RE; Gutierrez-Hartmann A
Nucleic Acids Res; 2001 Mar; 29(5):1251-60. PubMed ID: 11222776
[TBL] [Abstract][Full Text] [Related]
23. The TERT Promoter: A Key Player in the Fight for Cancer Cell Immortality.
Hasanau TN; Pisarev EP; Kisil OV; Zvereva ME
Biochemistry (Mosc); 2023 Jan; 88(Suppl 1):S21-S38. PubMed ID: 37069112
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
25. ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
Meng D; Li Z; Ma X; Wu L; Fu L; Qin G
Life Sci; 2020 Jul; 253():117693. PubMed ID: 32325133
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells.
Hsu CP; Lee LW; Tang SC; Hsin IL; Lin YW; Ko JL
Tumour Biol; 2015 Jul; 36(7):5389-98. PubMed ID: 25680408
[TBL] [Abstract][Full Text] [Related]
28. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
Yuan X; Dai M; Xu D
Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
[TBL] [Abstract][Full Text] [Related]
31. A role for the mitogen-activated protein kinase in mediating the ability of thyrotropin-releasing hormone to stimulate the prolactin promoter.
Wang YH; Maurer RA
Mol Endocrinol; 1999 Jul; 13(7):1094-104. PubMed ID: 10406461
[TBL] [Abstract][Full Text] [Related]
32. Etv5, an ETS transcription factor, is expressed in granulosa and cumulus cells and serves as a transcriptional regulator of the cyclooxygenase-2.
Eo J; Han K; M Murphy K; Song H; Lim HJ
J Endocrinol; 2008 Aug; 198(2):281-90. PubMed ID: 18492810
[TBL] [Abstract][Full Text] [Related]
33. Toward
Dalva-Aydemir S; Akyerli CB; Yüksel ŞK; Keskin H; Yakıcıer MC
OMICS; 2019 Oct; 23(10):486-495. PubMed ID: 31549911
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
35.
Rusinek D; Pfeifer A; Cieslicka M; Kowalska M; Pawlaczek A; Krajewska J; Szpak-Ulczok S; Tyszkiewicz T; Halczok M; Czarniecka A; Zembala-Nozynska E; Chekan M; Lamch R; Handkiewicz-Junak D; Ledwon A; Paliczka-Cieslik E; Kropinska A; Jarzab B; Oczko-Wojciechowska M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32560331
[TBL] [Abstract][Full Text] [Related]
36. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
[TBL] [Abstract][Full Text] [Related]
37. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
38. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the role of the mitogen-activated protein kinase in mediating cyclic-adenosine 3',5'-monophosphate effects on prolactin promoter activity.
Kievit P; Lauten JD; Maurer RA
Mol Endocrinol; 2001 Apr; 15(4):614-24. PubMed ID: 11266512
[TBL] [Abstract][Full Text] [Related]
40. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
